Tyligand Bioscience Ltd. has reported new dual-drug antibody-drug conjugates comprising monoclonal antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonist and a cytotoxic drug.
Bolt Biotherapeutics Inc. has prepared and tested new immunoconjugates comprising antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists. They are designed for potential use in the treatment of cancer.
University of Michigan has disclosed prodrugs of stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorder and infections.
Samjin Pharmaceutical Co. Ltd. has disclosed stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, allergy, autoimmune diseases and inflammatory disorders.
Pancreatic ductal adenocarcinom a (PDAC), frequently detected at advanced stages, has a 5-year survival rate of 12%. Metastases are common, including hepatic metastasis, which is particularly lethal due to the liver’s immune-tolerant environment and rich blood supply that facilitate tumor growth.
Primelink Biotherapeutics (Shenzhen) Co. Ltd. has synthesized stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.
The standard treatment for non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guérin (BCG). However, despite it being effective, many patients experience recurrences, and others become unresponsive. The activation of the intracellular transmembrane receptor stimulator of interferon genes (STING) has shown antitumoral effects in murine cancer models.
Polypid Ltd. has entered into a new research and development collaboration with Immunogenesis Inc. for the development of novel formulations utilizing Polypid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology and Immunogenesis’ potent STING agonist drug candidate to potentially enhance treatment for solid tumors.
Shenzhen Genuine Biotech Co. Ltd. has disclosed stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer. An exemplified compound significantly reduced tumor growth in experiments.
